NCT04690387View on ClinicalTrials.gov

Dendritic Cell Vaccine, AV-COVID-19, to Prevent COVID-19 Infection

PHASE1CompletedINTERVENTIONAL
Enrollment

27

Participants

Timeline

Start Date

December 7, 2020

Primary Completion Date

January 13, 2021

Study Completion Date

January 15, 2021

Conditions
COVID-19
Interventions
BIOLOGICAL

AV-COVID-19

Autologous dendritic cells previously incubated with SARS-CoV-2 spike protein

OTHER

GM-CSF

GM-CSF as an adjuvant

Trial Locations (1)

50244

Rumah Sakit Umum Pusat Dr. Kariadi, Semarang

Sponsors
All Listed Sponsors
collaborator

PT AIVITA Biomedika Indonesia

UNKNOWN

collaborator

Indonesia Ministry of Health

UNKNOWN

collaborator

National Institute of Health Research and Development, Ministry of Health Republic of Indonesia

OTHER

lead

Aivita Biomedical, Inc.

INDUSTRY

NCT04690387 - Dendritic Cell Vaccine, AV-COVID-19, to Prevent COVID-19 Infection | Biotech Hunter | Biotech Hunter